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Blue toe syndrome is the most frequent manifestation of tissue ischemia caused by
cholesterol embolization (CE), which can lead to amputation of affected lower extre-
mities, if severe. However, any effective treatment is lacking. We experienced a case of
spontaneously presenting blue toe syndrome and concomitant acute renal failure in a
patient with multiple atherosclerotic risk factors. CE was conﬁrmed by renal biopsy.
Despite medical treatment including prostaglandin therapy and narcotics, the toe lesion
progressed to gangrene with worsening ischemic pain. Therefore, we performed lumbar
sympathectomy, which provided dramatic pain relief as well as an adequate blood ﬂow
to the ischemic lower extremities, resulting in healing of the gangrenous lesion and
avoiding toe amputation. This is the ﬁrst reported case of a patient with intractable
ischemic toe syndrome caused by CE that was treated successfully by sympathectomy.
Our observations suggest that sympathectomy may be beneﬁcial in some patients with
CE-associated blue toe syndrome.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cholesterol embolization (CE) is a potentially serious mani-
festation of systemic atherosclerosis associated with high mor-
bidity and mortality. Although CE can occur spontaneously, it is
recognized as an iatrogenic complication of an invasive vascular
procedure, such as manipulation of the aorta during angioplasty
or vascular surgery, or after anticoagulation and ﬁbrinolytic
therapy [1]. The clinical manifestation of CE is characterized by
a shower of microemboli, leading to the occlusion of smalln Society of Nephrology. Publi
c-nd/4.0/).
y, Department of Internal
ed Heart Hospital, 445,vessels and associated inﬂammatory responses in a variety of
organs including the kidney, skin, brain, gastrointestinal tract,
and the extremities [1–4]. The frequency of skin ﬁndings in CE
is high, ranging from 35% to 96% [3]. In the lower extremities, CE
may lead to a sudden development of purple or blue toes and
discoloration of other regions of the foot. Because of the
frequent occurrence of blue toes in association with CE, the
term blue toe syndrome is occasionally used as a synonym for
CE syndrome. However, speciﬁc treatment has not been estab-
lished. Current treatment consists mainly of supportive care and
secondary prophylaxis against further episodes of CE.
Herein, we report a case of spontaneously presenting blue
toe syndrome caused by CE and accompanied by acute renal
failure, in which lumbar sympathectomy relieved toe pain
signiﬁcantly and improved local blood ﬂow in the ischemic
lower extremities.shed by Elsevier. This is an open access article under the CC BY-NC-ND
Figure 1. Improvement of the blue toe after sympathectomy. (A) Ulcer and purpuric discoloration are seen on the toes. (B) Post sympathectomy,
gangrenous lesion on the left ﬁfth toe is healed.
Figure 2. Renal biopsy. Occluded artery with biconvex needle-shaped
cholesterol cleft is shown (hematoxylin and eosin stained,
100magniﬁcation).
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A 76-year-old man was admitted to our hospital for
examination and treatment of a painful ulcer on the left ﬁfth
toe (Fig. 1A). He was a 75 pack-year smoker and had hyperten-
sion, dyslipidemia, and chronic kidney disease. On admission,
his blood pressure was 200/100 mmHg. He presented with a
blue and purple discoloration of his toe and weak pedal
arterial pulses. The white blood cell count was 14,000/mL with
2.2% eosinophil concentration, with increases in the erythro-
cyte sedimentation rate and C-reactive protein level. Serum
creatinine level increased from 2.7 to 6.5 mg/dL within
1 month. Urinalysis demonstrated 1þ proteinuria, and one
red and one white cell per high-power ﬁeld. Tests for anti-
nuclear antibody, anti-DNA antibody, and antineutrophil cyto-
plasmic antibody were negative. The C3 level was decreased
slightly. A renal ultrasound with Doppler showed both kidneys
to have normal size and blood ﬂow. The fundoscopic examina-
tion revealed no evidence of cholesterol emboli. Because of
unexplained renal failure in the absence of any recent CE-
associated vascular procedure or anticoagulation therapy, a
kidney biopsy was performed subsequently to identify any
treatable causes of acute kidney injury. The biopsy demon-
strated an interlobular renal artery occluded by atheromatous
material with a characteristic needle-shaped cholesterol cleft(Fig. 2). The patient's renal function deteriorated further and
hemodialysis was initiated. His toe ulcer progressed to gangrene
with ischemic pain, which was unresponsive to narcotics and
prostaglandin therapy. Computed tomography (CT) angiography
showed extensive atherosclerotic calciﬁed plaques with throm-
bus, mild aneurysmal dilatation of the abdominal aorta, and
total, bilateral occlusion of the tibial and peroneal arteries
(Fig. 3A). We could not consider surgical or endovascular
therapy because of the poor general condition of the patient
and a risk of repeated embolism. Instead, we chose lumbar
sympathectomy as a pain-relieving procedure. An anesthesiologist
performed percutaneous chemical lumbar sympathectomy with
8 mL of 99% ethanol at the L2–L3 level under ﬂuoroscopic
guidance. Shortly after alcohol sympathetic neurolysis, the
patient's systolic blood pressure dropped transiently to 70mmHg
but stabilized immediately with normal saline administration
alone. Following sympathectomy, toe pain was relieved dramati-
cally with an improvement in Visual Analogue Scale (VAS) score to
three points, from a previous eight points. The gangrenous lesion,
which was considered for amputation previously also healed
(Fig. 1B). In fact, he could walk without pain. Subsequent CT
angiography showed improvement in blood ﬂow in the ischemic
lower extremities (Fig. 3B). Renal function did not recover, and the
patient was transferred to a chronic dialysis program. One year
since, the ischemic toe pain has not recurred.Discussion
Blue toe syndrome is a frequent and serious cutaneous
manifestation of tissue ischemia and is caused by CE. Further-
more, the highest rates of cutaneous involvement have been
reported in patients with a concomitant renal manifestation of
CE [3]. If microvascular ischemia is severe, tissue necrosis may
develop, ranging in severity from small superﬁcial ulcerations to
gangrene, thus leading to amputation [5]. Since cholesterol
emboli occlude smaller arteries and arterioles rather than super-
ﬁcial large palpable arteries, many patients presenting with
disabling blue toe syndrome may not be candidates for direct
arterial intervention. Moreover, many reports suggest that such
an arterial intervention can induce secondary CE and contrast
nephrotoxicity, further aggravating renal function [6]. Surgery
(endarterectomy or bypass with exclusion of the source of
emboli) can be a treatment option; however, it is rarely indicated
because the origin of cholesterol crystal embolization is often not
certain. Moreover, many patients have a poor physical condition
with a serious cardiovascular disease or renal dysfunction.
Figure 3. Computed tomography angiography ﬁndings. (A) Near-total occlusion of both tibial and peroneal arteries can be seen. (B) Blood ﬂow is
restored to the ischemic lower extremities following sympathectomy.
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itself associated with substantially high morbidity and mortality
[1]. These factors were also true for our patient. In our case, the
patient experienced medically intractable ischemic pain and
secondary infection of a gangrenous toe. Therefore, toe amputa-
tion was the only reasonable choice. In this situation, lumbar
sympathectomy markedly improved wound healing as well as
ischemic pain by increasing blood ﬂow to the ischemic area,
leading to “limb salvage.”
Prior to the era of direct arterial surgery, lumbar sym-
pathectomy was performed in virtually all forms and stages of
peripheral vascular occlusive disease, Buerger's disease, and
some vasospastic disorders. A beneﬁt of sympathectomy is
explained as its circulatory effect by diminishing vasoconstric-
tor tone, thereby increasing blood ﬂow to the ischemic area. In
addition, an analgesic effect is produced by the interruption of
sympathetic–nociceptive coupling and by direct neurolytic
action on nociceptive ﬁbers [7,8]. With the advent of direct
arterial manipulation, lumbar sympathectomy is considered
old fashioned and an adjunctive treatment for limb salvage in
patients with unreconstructable peripheral vascular disease
[7,9,10]. Moreover, consistency and long-term effectiveness of
sympathectomy are debatable. Some clinicians consider it to
be of very little value in current practice. However, as shown in
our case, no demonstrable efﬁcacious treatment exists for blue
toe syndrome secondary to CE, and any therapeutic approach
that may be of beneﬁt deserves consideration. In this situation,
lumbar sympathectomy may be worthy of consideration as a
valuable, alternative treatment option.
Both randomized controlled and cohort studies have been
conducted to investigate symptom control and long-term beneﬁts
of lumbar sympathectomy, but many have failed to identify
objective beneﬁts. Nevertheless, multiple studies have shown
consistent symptom control in many patients with critical limb
ischemia, in which patient selection has been found to play a
major role [11–13]. In other words, the effect of sympathectomy
remains controversial probably because of a lack of a standard
method of patient selection. Although there is no deﬁnitive
preprocedural measure to predict outcomes for sympathectomy,
many reports suggest that sympathectomy may be ineffective inthe presence of extensive tissue necrosis far beyond gangrene of
individual toes or in the presence of an ankle brachial pressure
index of r0.3 [7–10]. Also, diabetic patients are generally
perceived to have little response to sympathectomy because they
are often autosympathectomized. However, the primary effect of
lumbar sympathectomy is based on the abolition of increased
vasomotor tone, and such tone can be expected to be normal in
great majority of diabetic patients, even in severe diabetic
neuropathy [14]. Therefore, vasomotor reactivity tests can be
helpful in determining whether or not to perform sympathect-
omy in patients with diabetes mellitus. We assume that these
prognostic markers obtained through the above tests can also be
useful for patient selection and indication of lumbar sympathect-
omy in blue toe syndrome caused by CE. Unfortunately, in our
case, the ankle brachial pressure index test, which might provide
objective data regarding limb circulation and collateral vessels
available to respond to sympathectomy, was not performed.
Although large, randomized controlled studies with long-
term follow-up examination periods are needed, Lee et al [10]
performed a retrospective review of 45 patients with toe
gangrene that were considered unamenable to direct arterial
surgery and were thus managed by lumbar sympathectomy
alone. At the 5- and 8-year follow-up examination, cumulative
limb salvage was 71% and cumulative toe salvage 51%, indicat-
ing a possibility that the effect of sympathectomy can be
durable. Moreover, chemical lumbar sympathectomy is a rela-
tively inexpensive, minimally invasive, and safe procedure, with
a low incidence of signiﬁcant morbidity [8,9]. Adverse events
associated with lumbar sympathectomy have been reported to
be temporary in most cases, and major complications are
infrequent. Complications include neurological, renal and ure-
teric, vascular, and other miscellaneous concerns. Genitofemoral
neuralgia is the commonest complication of lumbar sym-
pathectomy, with an incidence of approximately 5–10%. How-
ever, the duration rarely exceeds 2–6 weeks, and symptoms
usually tend to regress spontaneously or can be relieved by
simple analgesics. Failure of ejaculation may follow sym-
pathectomy if the ﬁrst lumbar ganglion is ablated, and this
occurs more commonly after bilateral procedures. Subarachnoid
injection, epidural injection, aseptic meningitis, and paraplegia
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capsule, or the ureter can occur, and the use of ﬂuoroscopic
guidance or CT can reduce these complications greatly. Vascular
complications include possible penetration of inferior vena
cava, injury of arteries, and hypotension. Retroperitoneal hema-
toma formation has been described in anti-coagulated patients.
Other miscellaneous complications that have been reported
include allergic reactions to contrast media and injury of the
intervertebral disc without adverse consequences [9,15].
Sympathectomy may therefore be justiﬁed in patients at risk
of limb loss for which surgical reconstruction or angioplasty is
not possible, in the hope that a few selected proportion may
beneﬁt, even if the beneﬁt proves to be temporary.
To the best of our knowledge, this is the ﬁrst reported case of
blue toe syndrome treated via sympathectomy in a patient with
acute renal failure caused by CE, although several therapeutic
approaches such as prostaglandin analogue, corticosteroid ther-
apy, and statin use have been attempted with or without
success in similar situations [6]. Lumbar sympathectomy may
be a valuable alternative therapeutic modality in properly
selected patients experiencing intractable, progressive ischemic
toe disease, unamenable to other treatments and caused by CE.
Larger clinical trials are needed to conﬁrm our observations.Conﬂicts of interest
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